ATC level alterations
List of latest ATC/DDD decisions from the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the decisions should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline (see list). If no objections are received, the new ATC/DDD decisions will be considered final and included in the ATC/DDD Index. In the list final indicates that the date for objection has expired. The year of implementation in the ATC/DDD Index is given in the list.
Please note that the ATC and DDD alterations are only valid and implemented in the coming annual updates of January 1st.
Previous ATC code | ATC level name | New ATC code | Deadline for objection to temporary alterations | Implementation in ATC/DDD index |
---|---|---|---|---|
L01EX17 | capmatinib | L01EP01 | 01.02.2025 | 2026 |
L01EX21 | tepotinib | L01EP02 | 01.02.2025 | 2026 |
L04AA58 | efgartigimod alfa | L04AL01 | 01.02.2025 | 2026 |
L04AG16 | rozanolixizumab | L04AL02 | 01.02.2025 | 2026 |
Last updated: 2024-12-11